Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 562 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Potassium Chloride Clear all
Completed Phase 3 Interventional Results available

Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial

NCT00310375
View directory record Official record
Conditions
Epilepsy
Interventions
Ezogabine: USAN Retigabine (International Nonproprietary Name)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
30
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Stain and Plaque Removal Capability of Two Experimental Potassium Nitrate Dentifrices

NCT03267511
View directory record Official record
Conditions
Oral Hygiene
Interventions
5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica, 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP, 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica, 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension

NCT01682837
View directory record Official record
Conditions
Hypertension
Interventions
Potassium chloride powder, Potassium citrate powder, Potassium magnesium citrate powder, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Not applicable Interventional

A Single Session Pain Psychology Class for Spine Surgery Patients

NCT03985436
View directory record Official record
Conditions
Lumbar; Injury
Interventions
Trek for Surgical Success
Behavioral
Lead sponsor
Sara Davin, PsyD, MPH
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 20, 2026, 11:02 PM EDT
Completed No phase listed Observational

Effect of Viscous Fiber on Postprandial Kalemic Response in Hemodialysis Patients

NCT05086185
View directory record Official record
Conditions
Hyperkalemia, Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
Kalemic Response to Orange Juice, Kalemic Response to Orange Juice with Fiber
Diagnostic Test · Dietary Supplement
Lead sponsor
University of Nevada, Reno
Other
Eligibility
18 Years to 89 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 20, 2026, 11:02 PM EDT
Not yet recruiting Not applicable Interventional

Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease

NCT05558267
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Standard Table Salt, Salt Substitute
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 3 Interventional

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis

NCT04102371
View directory record Official record
Conditions
Shock, Septic
Interventions
Lactated Ringer, Normal Saline, Plasma-lyte
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Months to 17 Years
Enrollment
9,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
22
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 3 Interventional

A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections

NCT00643292
View directory record Official record
Conditions
Acute Otitis Media
Interventions
amoxicillin/clavulanate postassium (Augmentin ES-600), azithromycin SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 48 Months
Enrollment
902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Bellflower, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 17, 2011 · Synced Oct 20, 2026, 11:02 PM EDT
Recruiting Phase 2 Interventional

SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

NCT05138575
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Empagliflozin + Potassium Chloride, Empagliflozin + Potassium Nitrate, Potassium Chloride + Placebo for Empagliflozin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

NCT00232596
View directory record Official record
Conditions
Seizures
Interventions
Retigabine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
32
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 20, 2026, 11:02 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Transformative Research in Diabetic Nephropathy 2.0

NCT07444203
View directory record Official record
Conditions
Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Potassium Citrate to Prevent Age Related Bone Loss

NCT00282126
View directory record Official record
Conditions
Osteoporosis
Interventions
Potassium citrate
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 20, 2026, 11:02 PM EDT
Recruiting Phase 4 Interventional

Low Sodium Oxybate in Patients With Idiopathic Hypersomnia

NCT05837091
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
Low Sodium Oxybate, 24-hour polysomnography, Nextsense EEG earbuds, Axivity device
Drug · Diagnostic Test · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Redwood City, California • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Not applicable Interventional Results available

Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate

NCT02665117
View directory record Official record
Conditions
Hypertension
Interventions
Potassium Magnesium Citrate (KMgCit), Potassium Chloride (KCl), Chlorthalidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
3
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between Raltegravir And UK-453,061

NCT00784420
View directory record Official record
Conditions
Healthy Volunteers
Interventions
UK-453,061, Raltegravir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 18, 2008 · Synced Oct 20, 2026, 11:02 PM EDT
Completed No phase listed Observational

Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas

NCT02362308
View directory record Official record
Conditions
Primary Aldosteronism
Interventions
Adrenalectomy, mineralocorticoid receptor antagonist
Other · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial of Nano-hydroxyapatite-Containing Toothpastes for Relief of Dentin Hypersensitivity

NCT04590040
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Placebo, 15% nano-HAP toothpaste, 5% KNO3 toothpaste
Other · Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
20 Years to 80 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 20, 2026, 11:02 PM EDT
Recruiting Phase 4 Interventional

Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis

NCT06076304
View directory record Official record
Conditions
Sinus Infection, Acute Sinusitis
Interventions
amoxicillin/clavulanate potassium, Placebo, Budesonide nasal spray
Drug
Lead sponsor
Daniel Merenstein
Other
Eligibility
18 Years to 75 Years
Enrollment
3,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Hyattsville, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Pre-Run Nutritional Supplements During a Fixed-Pace 5 km Treadmill Run

NCT07854223
View directory record Official record
Conditions
Exercise Physiology, Nutritional Supplementation
Interventions
Caffeine, L-Citrulline, Exogenous Ketone (Beta-Hydroxybutyrate), placebo beverage
Dietary Supplement · Other
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 1 Interventional

Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)

NCT00591643
View directory record Official record
Conditions
Adrenal Tumors, Adrenal Malignancies, Abnormal Hormonal Secretions, Electrolytes Abnormalities
Interventions
Imaging, Adrenal acans, (NP-59)
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1977 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Inorganic Nitrate Supplement on Blood Pressure

NCT03909789
View directory record Official record
Conditions
Blood Pressure, Endothelial Dysfunction
Interventions
Plant based bioequivalent Nitrate supplementation, Placebo
Dietary Supplement
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 1 Interventional Results available

The Effects of Potassium Nitrate in Reducing Dentinal Hypersensitivity

NCT01587950
View directory record Official record
Conditions
Dentinal Hypersensitivity, Dental Pain
Interventions
Potassium Nitrate, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Not applicable Interventional Results available

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

NCT00814879
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections
Interventions
Raltegravir, Atazanavir, Standard treatment regimen
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
New Haven, Connecticut • Waterbury, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Not applicable Interventional

A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals

NCT00000648
View directory record Official record
Conditions
HIV Infections, Neurosyphilis
Interventions
Penicillin G potassium, Ceftriaxone sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
42
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 20, 2026, 11:02 PM EDT